Skip to main content

Advertisement

Table 3 Patient-reported outcomes

From: Characteristics of the first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia: a cross-sectional observational study

Parameter Mean estimate Diff. 95 % CI p
Lower Upper
1MTP pain VAS (mm) Control (ref.) 1.7     
Gout 8.4 6.7 1.4 12.0 0.014
Asymptomatic hyperuricaemia 6.6 4.9 −0.1 10.0 0.055
General pain VAS (mm) Control (ref.) 18.0     
Gout 21.8 3.8 −9.9 17.5 0.581
Asymptomatic hyperuricaemia 29.2 11.3 −1.7 24.3 0.088
Patient global VAS (mm) Control (ref.) 11.5     
Gout 23.6 12.0 0.9 23.1 0.034
Asymptomatic hyperuricaemia 21.3 9.8 −0.8 20.3 0.068
HAQ-DI Control (ref.) 0.11     
Gout 0.44 0.33 0.13 0.54 0.002
Asymptomatic hyperuricaemia 0.32 0.21 0.02 0.41 0.033
LLTQ - daily Control (ref.) 38.6     
Gout 33.3 −5.3 −8.6 −2.0 0.002
Asymptomatic hyperuricaemia 35.0 −3.6 −6.8 −0.4 0.026
LLTQ – recreational Control (ref.) 34.2     
Gout 20.8 −13.4 −19.0 −7.9 <0.001
Asymptomatic hyperuricaemia 27.2 −7.0 −12.3 −1.8 0.010
MFPDI Control (ref.) 1.826     
Gout 13.3 11.5 7.7 15.3 <0.001
Asymptomatic hyperuricaemia 3.0 1.2 −2.4 4.8 0.511
    Odds ratio 95 % CI for OR p
Lower Upper
Presence of disabling foot pain Control (ref.)      
Gout   13.4 3.69 48.68 <0.001
Asymptomatic hyperuricaemia   4.2 1.36 12.8 0.013